# Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

> **NCT05065411** · PHASE3 · TERMINATED · sponsor: **Veru Inc.** · enrollment: 5 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Enobosarm & Abemaciclib Combo
- **DRUG:** non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant

## Key facts

- **NCT ID:** NCT05065411
- **Lead sponsor:** Veru Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-11
- **Primary completion:** 2023-10-19
- **Final completion:** 2024-01-09
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2024-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05065411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05065411, "Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05065411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*